Safety and efficacy of a novel ANGPTL4 inhibitory antibody for lipid lowering: results from phase 1 and phase 1b/2a clinical studies

Journal:

The Lancet

Published:

2025-05-16

DOI:

10.1016/s0140-6736(25)00825-6

Affiliations:

6

Authors:

28

Go to article

Institutions	Authors	Share
Novartis Biomedical Research, United States of America (USA)	16.000000 16.000000	0.57
Marea Therapeutics, Inc., United States of America (USA)	11.000000 11.000000	0.39
University of Pennsylvania (Penn), United States of America (USA)	1.000000	0.04

Interested in Cardiovascular Medicine and Haematology?